Healthcare
Sienna Biopharmaceuticals, Inc.(SNNAQ)
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 โ Jun 16, 2026
- Market Cap
- โ
- Revenue Growth
- 0.0%
- EPS Growth
- +30.8%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 23, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sienna Biopharmaceuticals, Inc. (SNNAQ) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +30.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +30.8%, free cash flow -49.3% with operating margin 0.0% and ROIC -92.0%. Stock Foundry combines SNNAQ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2019 was reported on Nov 12, 2019, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +30.8%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2019 Nov 12, 2019 | โ | +0.0% | +0.0% | +0.0% |
2019 Aug 8, 2019 | +32.5% | +0.0% | +0.0% | +0.0% |
2019 May 8, 2019 | -26.0% | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SNNAQ
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SNNAQ Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SNNAQ and SPY.
Company Overview
Sienna Biopharmaceuticals, Inc.
Other OTC
Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a topical suspension of silver particles, which is in pivotal clinical trials for the treatment of acne, as well as for the reduction of light-pigmented hair, including white, gray, blonde, light brown, and light red hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California. On December 18, 2019, Sienna Biopharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on September 16, 2019.
- Leadership
- David E. I. Pyott
- IPO Date
- Jul 27, 2017
- Employees
- 13
- Street Address
- 30699 Russell Ranch Road
- Mailing
- Westlake Village, CA, 91362
- Region
- Westlake Village, CA, US
- Reporting Currency
- USD
- Investor Line
- 818-629-2256
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 0.2
- Price/Sales
- โ
- Price/Book
- 0.0
Growth
- Revenue
- 0.0%
- EPS
- +30.8%
- Free Cash Flow
- -49.3%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -59.8%
- ROIC
- -92.0%
Balance Sheet
- Debt/Equity
- 0.19
- Current Ratio
- 2.07
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.